The U.S. Food and Drug Administration has reported shortages of the chemotherapy platinum drugs
carboplatin and
cisplatin. The
Society of Gynecologic Oncology has indicated that these shortages may necessitate alternative treatments to be used to avoid delays in treating patients' cancer.
The Office of the Commissioner of Insurance (OCI) encourages health plan issuers to work with providers and consider flexibility around the use of alternative agents when a platinum agent would normally be used, to ensure that insured individuals receive timely treatment for cancer.
Any questions concerning this bulletin may be directed to Sarah Smith at Sarah.Smith2@wisconsin.gov.